Scholarly Works

Comment and reply on: The cost-effectiveness of...

Journal article

Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

Abstract

Correspondence on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis [Lanctôt KL et al., Curr Med Res Opin 2009; 24: 3223-37; doi:10.1185/03007990802484234]

Authors

L. RJ; L. LK; Bosco P; Charles H; Aaron C; Jean-Eric T

Journal

Current Medical Research and Opinion, Vol. 25, No. 7, pp. 1631–1633

Publisher

Taylor & Francis

Publication Date

July 1, 2009

DOI

10.1185/03007990902993415

ISSN

0300-7995

Associated Experts

Bosco Paes

Professor Emeritus, Faculty of Health Sciences

Jean-Eric Tarride

Professor, Faculty of Health Sciences

Labels

Fields of Research (FoR)

3213 Paediatrics 32 Biomedical and Clinical Sciences 3206 Medical biotechnology 4003 Biomedical engineering

Sustainable Development Goals (SDG)

3 Good Health and Well Being

Medical Subject Headings (MeSH)

Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Canada Cohort Studies Cost-Benefit Analysis Gestational Age Humans Infant, Newborn Infant, Premature Palivizumab Respiratory Syncytial Virus Infections Respiratory Syncytial Virus Vaccines

View published work (Non-McMaster Users)

View published work (McMaster Users)

Contact the Experts team

Get technical help

or

Provide website feedback